-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $51

Benzinga·04/14/2025 14:53:03
Listen to the news
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target from $38 to $51.